Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NABILONE

All products: general benefit

Other products in the same Health Canada class (A04A, A04AD) — coverage varies; not interchangeable

  • Aprepitant (Emend Tri-Pack): limited Use 452, 453
  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit

Cesamet · DIN 00548375 · 1mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Cesamet (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Cesamet · DIN 00548375 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-05-27 · brand CESAMET · ATC A04AD11 NABILONE · form Capsule · route Oral · ingredients NABILONE 1 MG · company Bausch health, canada inc. · schedule Narcotics (cdsa ii)
Check this DIN again · Health Canada product record

Ministry pays: $3.6669 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4941 · Verify on the e-Formulary ↗ (DIN 00548375)

Source record
DIN 00548375: Cesamet Raw flags: sec3=Y Item: 562200011; group id 668; item number 1658; lccId None; manufacturer id VAL Source form: Cap; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $8.5254; ministry $3.6669 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00548375 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4941
Interchangeable products
PMS-Nabilone · DIN 02380919 · $3.6669 Teva-Nabilone · DIN 02384892 · $3.6669
Shortage status: resolved shortage (ended 2018-11-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00548375
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL 56:22 Antiemetics and Antinauseants

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS Adults: > 18 years N CESAMET® (nabilone) is indicated for the management of severe nausea and vomiting associated with cancer chemotherapy. Pediatrics: < 18 years The safety and efficacy of NCESAMET® in the pediatric population have not been established and its use is not recommended in this patient population. Geriatrics: > 65 years N CESAMET® should be used with caution in the elderly (see PRECAUTIONS). N CESAMET® Product Monograph Page 2 of 16 https://pdf.hres.ca/dpd_pm/00051389.PDF PM date: May 24, 2019 Source product: CESAMET; DIN 00548375; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.